Vitrea sparks Vital Images results
Sales of its Vitrea 3-D visualization workstation helped Vital Images report sharply higher revenues for its first quarter (end-March), although the company’s net loss grew as well. For the period, the Minneapolis company posted sales of $766,000,
Sales of its Vitrea 3-D visualization workstation helped Vital Images report sharply higher revenues for its first quarter (end-March), although the companys net loss grew as well. For the period, the Minneapolis company posted sales of $766,000, compared with revenues of $156,000 in the first quarter of 1997. Vitrea began shipping in October, and in the most recent period contributed $488,000 to Vital Images revenues.
The companys net loss for the first quarter was $1.1 million, compared with a net loss of $873,000 for the first quarter of 1997. The net loss for the most recent period included a charge of $180,000 in connection with the departure of Vital Images former CEO, Andrew Weiss (SCAN 2/18/98).
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
